The Research Center for Nano-Biomaterials, Analytical and Testing Center, Sichuan University, Chengdu 610064, China.
J Biomed Mater Res B Appl Biomater. 2010 Oct;95(1):36-46. doi: 10.1002/jbm.b.31680.
The purpose of this study is to explore and develop biodegradable scaffold for bone regeneration or tissue engineering with the capacity of controlled drug delivery. Ceftazidime as a model drug was encapsulated in ethyl cellulose (EC) microspheres, which were subsequently incorporated in a hydroxyapatite/polyurethane (HA/PU) composite scaffold to generate an antibiotic drug delivery system. HA/PU scaffolds had an interconnected pore network with an average porosity of about 83%. The presence of microspheres in the composite scaffolds was confirmed by scanning electron microscopy. The drug-loaded EC microspheres were uniformly distributed in the HA/PU scaffold matrix and showed no significant effect on the pore structure of the scaffold. Incorporation of microspheres into scaffolds significantly reduced the initial burst release, and the system exhibited a sustained release of the model drug for up to 60 days. Moreover, the scaffold with drug-loaded microspheres was proved to be an effective drug delivery system with good cytocompatibility and antibacterial properties. The novel drug-loaded microsphere/scaffold composites developed in this study are promising to serve as vehicles for controlled drug delivery in bone regeneration or bone tissue engineering.
本研究旨在探索和开发可生物降解的支架用于骨再生或组织工程，具有控制药物释放的能力。头孢他啶作为模型药物被包封在乙基纤维素（EC）微球中，随后将其掺入到羟基磷灰石/聚氨酯（HA/PU）复合支架中，以产生抗生素药物递送系统。HA/PU 支架具有相互连接的孔网络，平均孔隙率约为 83%。扫描电子显微镜证实了微球在复合支架中的存在。载药 EC 微球均匀分布在 HA/PU 支架基质中，对支架的孔结构没有显著影响。微球的掺入显著降低了初始突释，该系统表现出模型药物长达 60 天的持续释放。此外，载药微球的支架被证明是一种具有良好细胞相容性和抗菌性能的有效药物递送系统。本研究开发的新型载药微球/支架复合材料有望作为骨再生或骨组织工程中控制药物释放的载体。
